Home Latest Articles
Latest Articles
  • Qian ZHANG, Dongsheng CHENG, Niansong WANG
    World Clinical Drug. 2025, 46(1): 14-18.

    Chronic kidney disease(CKD) has long been an important global health problem, and renal anemia(RA)is one of the important complications of CKD, which is closely related to the increase of all-cause mortality and cardiovascular mortality in patients. The occurrence of RA is related to the deficiency of erythropoietin(EPO) production.EPO related drugs are an important treatment for RA and affect the prognosis of patients with CKD. This article reviewed the application progress of EPO related drugs in RA in recent years, in order to provide some reference for clinic.

  • Chang LIU, Ying FAN, Niansong WANG
    World Clinical Drug. 2025, 46(1): 19-22.

    Iron metabolism disorder is common disorder in patients with chronic kidney disease, which leads to renal anemia(RA). Intravenous iron is an important treatment for RA, and commonly used drugs include ferric carboxymaltose,ferumoxytol and ferric derisomaltose. Based on the previous research results, this article reviewed the application progress of intravenous iron in RA, in order to provide some ideas for individualized iron therapy.

  • Qiannan ZHANG, Niansong WANG, Junhui LI
    World Clinical Drug. 2025, 46(1): 23-28.

    Secondary hyperparathyroidism(SHPT) is one of the most important complications of chronic kidney disease-mineral and bone disorder(CKD-MBD), which can significantly increase the risk of bone deformities,cardiovascular events, and death. In the current treatment of CKD-MBD SHPT, phosphorus binders, calcium-like agents,polynuclear iron-hydroxide and tenapanor have shown advantages. Novel active vitamin D analogues can effectively reduce the level of intact parathyroid hormone(iPTH). This article reviewed the recent progress of IPTH-decreasing CKD-MBD drugs in order to provide reference for clinical use.

  • Panpan SONG, Lili YU
    World Clinical Drug. 2025, 46(1): 29-37.
    Objective

    To investigate the effect of remimazolam on cognitive dysfunction induced by sevoflurane in rats by regulating Toll-like receptor(TLR)4/myeloid differentiation factor(MyD)88/nuclear transcription factor(NF)-κB pathway.

    Methods

    A total of 72 male SD rats were divided into A to F groups, 12 rats in each group. A group(50% air and oxygen mixture, 2 L/min) and other groups were treated with A group+2% sevoflurane to construct aged postoperative cognitive dysfunction rat model. After successful modeling, C groups to E were given(1.5 mg/kg, 3 mg/kg and 6 mg/kg remimazolam+intraperitoneal injection of the same amount of 0.9% sodium chloride injection), respectively, F group was given(6 mg/kg remimazolam+intraperitoneal injection of 75 μg RS09). The rats in A group and B group were injected with the same amount of 0.9% sodium chloride injection in the tail vein and abdominal cavity. The escape latency,the number of crossing platforms and the histopathology of hippocampus were observed. The expression of ionized calcium-binding adapter molecule(IBA)-1 was detected by immunofluorescence staining. Enzyme-linked immunosorbent assay was used to detect the levels of neuron-specific enolase(NSE), interleukin(IL)-6 , central nervous system specific protein S-100β, and tumor necrosis factor(TNF)-α in hippocampus. Terminal-deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling staining was used to detect neuronal apoptosis. TLR4, MyD88, Cleaved caspase-3 and p-NF-κB p65 proteins were detected by immunoblotting.

    Results

    Compared with B group, the disordered arrangement of neurons and cell morphological changes of rats in C ~ E group were improved, the escape latency was shortened, and the number of crossing platforms was increased. Levels of NSE, S-100β, IL-6, TNF-α, the number of IBA-1 positive cells,neuronal apoptosis rate, and the proteins levels of TLR4, MyD88, Cleaved Caspase-3, and p-NF-κB p65 were significantly decreased(P<0.05).

    Conclusion

    Remimazolam may improve sevoflurane-induced cognitive dysfunction in aged rats by inhibiting the TLR4/MyD88/NF-κB pathway.

  • Juanhui DUAN, Yong WANG
    World Clinical Drug. 2025, 46(1): 38-43.
    Objective

    To investigate the therapeutic effect of calcium and zinc gluconate oral solution on osteoporosis in ovariectomized rats.

    Methods

    72 SD rats were randomly divided into sham operation group, model group, positive control group and low, medium and high doses of Xingaite groups(3, 6, 12 ml/kg), with 12 rats in each group. Except for the sham operation group, the ovaries were removed to establish the osteoporosis model. The positive control group was given estradiol 0.1 mg/kg, and the sham operation group and the model control group were given the same volume of purified water by gavage for 99 days. The body mass of the rats was observed every 3 days. After treatment, bone mineral density(BMD), bone volume relative to tissue volume(BV/TV) and bone surface relative to tissue volume(BS/TV)were analyzed by micro-CT. Calcium, zinc and bone metabolism were detected by enzyme linked immunosorbent assay.

    Results

    Compared with the model group, the zinc-calcium group significantly inhibited the growth of body mass, increased the level of zinc, improved the bone loss of femur, increased trabecular number and connection and BMD, increased BV/TV and BS/TV, and decreased the levels of osteocalcin and procollagen type Ⅰ carboxy-terminal peptide.

    Conclusion

    Xingaite can improve the microstructure of bone trabecular in ovariectomized rats, increase bone density, slow down the osteoporosis process in ovariectomized rats, and has a good effect on ovariectomized rats with osteoporosis.

  • Xiaobei LI, Meiling HOU, Qingkai WANG, Xiaowei JI
    World Clinical Drug. 2025, 46(1): 44-49.
    Objective

    To observe the effect of modified Buyang Huanwu decoction combined with sacubitril valsartan on chronic cardiac failure(CHF).

    Methods

    A total of 120 CHF patients with Qi deficiency and blood stasis admitted to Cangzhou Integrated Traditional Chinese and Western Medicine Hospital from November 2021 to June 2023 were randomly divided into western medicine group(n=60) and Chinese and western medicine combined group(n=60). The western medicine group was treated with sacubitril valsartan on the basis of conventional treatment, and the Chinese and western medicine combined group was treated with modified Buyang Huanwu decoction on the basis of western medicine group, with a course of 3 months.

    Results

    After treatment, the traditional Chinese medicine syndrome score, quality of life score, N-terminal brain natriuretic peptide precursor, myocardial troponin T level and left ventricular mass index in the two groups were decreased compared with before treatment(P<0.05), the left ventricular ejection fraction and 6 min walking test were higher than those before treatment(P<0.05), and the above indexes in Chinese and western medicine combined group were better than those in western medicine group(P<0.05). The total effective rate of the combined group was obviously higher than that of the western medicine group(91.67% vs 76.67%, P<0.05). There was no significant difference in the incidence of adverse reactions between the combined group and western medicine group(8.33% vs 13.33%, P>0.05).

    Conclusion

    Modified Buyang Huanwu decoction combined with sacubitril valsartan has high curative effect on CHF, and can improve the heart function and quality of life of patients.

  • Ruijing LUO, Yong PENG, Yingjie WANG, Jie LIU, Zhuqian JIANG, Zongqin WU
    World Clinical Drug. 2025, 46(1): 50-54.
    Objective

    To explore the clinical efficacy of Siwanfeng decoction in treating atopic dermatitis(AD) in children with heart fire and spleen deficiency syndrome.

    Methods

    A total of 70 patients with AD who met the inclusion criteria were randomly divided into treatment group and control group, with 35 cases in each group. The treatment group was given Siwanfeng decoction orally, while the control group was given levocetirizine hydrochloride oral liquid orally.The treatment course was 6 weeks. The changes in scoring AD(SCORAD) scores and clinical efficacy were compared between two groups.

    Results

    The total effective rate of the treatment group was 97.14% and 40% in the control group,and the total effective rate of the treatment group was significantly higher than that of the control group(P<0.001). After treatment, the SCORAD score in the treatment group was decreased than before treatment and the control group, and the difference was statistically significant(P<0.001).

    Conclusion

    Siwanfeng decoction has a good clinical efficacy in treating children with AD with heart fire and spleen deficiency syndrome.

  • Tao XIAO, Yongtao SHEN, Minglin ZHOU
    World Clinical Drug. 2025, 46(1): 55-59.
    Objective

    To investigate the clinical efficacy of Yunpi Jiangzhi decoction combined with silymarin in the treatment of non-alcoholic steatohepatitis(NASH) with liver stagnation and spleen deficiency syndrome.

    Methods

    A total of 84 NASH patients treated in our outpatient department from July 2021 to December 2022 were selected as the study subjects. They were divided into control group(silymarin capsule) and combined treatment group(silymarin capsule combined with Yunpi Jiangzhi decoction) by simple rank randomization method, with 42 cases in each group.

    Results

    The total effective rate of combined treatment group was higher than that of control group(92.50% vs 75.00%,P<0.05). After treatment, the Traditional Chinese Medicine syndrome score, liver function and glucose and lipid metabolism levels of the combined treatment group were lower than those in the control group(P<0.05), while the glucose metabolic rate and high density lipoprotein cholesterol level were higher than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Yunpi Jiangzhi decoction combined with silymarin can improve the clinical efficacy and safety of NASH patients with liver stagnation and spleen deficiency syndrome.

  • Yu HE, Wei HE, Jing DU
    World Clinical Drug. 2025, 46(1): 60-65.
    Objective

    To investigate the effect of citalopram combined with pregabalin on pain degree and negative emotions in patients with postherpetic neuralgia.

    Methods

    A total of 103 patients with postherpetic neuralgia treated in our hospital from September 2022 to March 2023 were selected as the study objects. They were randomly divided into the observation group(n=52) and the control group(n=51). The observation group received pregabalin combined with citalopram, while the control group received pregabalin. The clinical efficacy, pain degree, anxiety, depression and cytokine changes were compared between the two groups.

    Results

    The clinical efficacy rate of the observation group was higher than that of the control group(94.23% vs 64.71%, P<0.05). After treatment, the visual analogue scale, Hamilton Anxiety Scale, Hamilton Depression Scale, the levels of interleukin-6 and tumor necrosis factor-α in the both groups were decreased than those before treatment, and the observation group was lower than the control group(P<0.05).

    Conclusion

    Pregabalin combined with citalopram can improve the clinical efficacy, effectively alleviate the pain, ameliorate the anxiety and depression, and attenuate the inflammation response in patients with postherpetic neuralgia.

  • Jie GAO, Yifang DENG, Minyu LIU
    World Clinical Drug. 2025, 46(1): 66-72.

    With the widespread use of antibiotics, the ongoing development of microbial resistance poses a significant threat to global health. Therefore, the search for new antibiotics or other antimicrobial resources has become the focus of global scientific research. Antimicrobial peptides(AMPs) have attracted much attention as excellent candidates for overcoming antibiotic resistance. AMPs are small molecular proteins that are naturally produced by all living organisms and play a crucial role in the host's innate immunity against a variety of microorganisms, including bacteria, fungi, and viruses. AMPs are widely found in various organisms such as microorganisms, plants, insects, and mammals. AMPs exert biological activity by targeting key molecules such as cell membranes, cell walls, DNA and proteins within cells. The wide range of sources and complex and diverse mechanisms provide a solid foundation for the wide application of AMPs. This article reviewed the classification of AMPs based on animal origin, the mechanisms and applications in pharmaceutical field, in order to provide professional reference for further research in related fields.

News